FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088610618> ?p ?o ?g. }

• W2088610618 endingPage "S313" @default.
• W2088610618 startingPage "S313" @default.
• W2088610618 abstract "Purpose/Objective(s)A variety of minimally invasive energy based modalities has been and continues to be investigated for the treatment of renal tumors. The goal of any such technique is definitive destruction of the lesion, preservation of the normal surrounding parenchyma, and minimal morbidity. It is the intent of this study to determine histologically whether Stereotactic Body Radiation Therapy (SBRT) can be applied to renal tumors safely and effectively.Materials/MethodsPatients with solitary renal tumor 4cm or less are offered pretreatment with SBRT followed by a partial nephrectomy 8 weeks later. Once enrolled in the study, the patient undergoes a CT scan, a CT-guided renal biopsy and percutaneous placement of a fiducial marker. A planning CT scan is done and SBRT planning is completed. In this dose escalation study, the initial radiation dose is 4 Gray delivered over 4 fractions in 2 days, for a total of 16 Gray. Subsequent groups of patients will be escalated to higher doses up to a total of 48 Gray in 4 fractions. Novalis gating technology is utilized in all patients. Eight weeks following the SRA treatment a preoperative CT scan is obtained and the patient undergoes an open or laparoscopic partial nephrectomy in the standard fashion. Pathologic evaluation is performed.ResultsTo date we have completed SRA in 6 patients. Mean age was 56.5 years. Female n = 3; Male n = 3. Mean tumor size: 1.67 cm. All patients tolerated the four fractions with no adverse events. The current dose level is 6 Gy times 4 fractions to a total dose of 24 Gy. Histologically, the first 2 patients had viable tumor. The remaining 4 patients had no residual tumor in the specimen. The mean follow-up time was 1.9 years (range, 0.7-2.69). No toxicities and no change in renal function were noted.ConclusionsWe have established that our targeting is precise utilizing the Novalis gating technology. We are extremely encouraged and cautiously optimistic with our initial results. We believe that pathologic confirmation of ablative technologies is essential for appropriate evaluation of efficacy. Purpose/Objective(s)A variety of minimally invasive energy based modalities has been and continues to be investigated for the treatment of renal tumors. The goal of any such technique is definitive destruction of the lesion, preservation of the normal surrounding parenchyma, and minimal morbidity. It is the intent of this study to determine histologically whether Stereotactic Body Radiation Therapy (SBRT) can be applied to renal tumors safely and effectively. A variety of minimally invasive energy based modalities has been and continues to be investigated for the treatment of renal tumors. The goal of any such technique is definitive destruction of the lesion, preservation of the normal surrounding parenchyma, and minimal morbidity. It is the intent of this study to determine histologically whether Stereotactic Body Radiation Therapy (SBRT) can be applied to renal tumors safely and effectively. Materials/MethodsPatients with solitary renal tumor 4cm or less are offered pretreatment with SBRT followed by a partial nephrectomy 8 weeks later. Once enrolled in the study, the patient undergoes a CT scan, a CT-guided renal biopsy and percutaneous placement of a fiducial marker. A planning CT scan is done and SBRT planning is completed. In this dose escalation study, the initial radiation dose is 4 Gray delivered over 4 fractions in 2 days, for a total of 16 Gray. Subsequent groups of patients will be escalated to higher doses up to a total of 48 Gray in 4 fractions. Novalis gating technology is utilized in all patients. Eight weeks following the SRA treatment a preoperative CT scan is obtained and the patient undergoes an open or laparoscopic partial nephrectomy in the standard fashion. Pathologic evaluation is performed. Patients with solitary renal tumor 4cm or less are offered pretreatment with SBRT followed by a partial nephrectomy 8 weeks later. Once enrolled in the study, the patient undergoes a CT scan, a CT-guided renal biopsy and percutaneous placement of a fiducial marker. A planning CT scan is done and SBRT planning is completed. In this dose escalation study, the initial radiation dose is 4 Gray delivered over 4 fractions in 2 days, for a total of 16 Gray. Subsequent groups of patients will be escalated to higher doses up to a total of 48 Gray in 4 fractions. Novalis gating technology is utilized in all patients. Eight weeks following the SRA treatment a preoperative CT scan is obtained and the patient undergoes an open or laparoscopic partial nephrectomy in the standard fashion. Pathologic evaluation is performed. ResultsTo date we have completed SRA in 6 patients. Mean age was 56.5 years. Female n = 3; Male n = 3. Mean tumor size: 1.67 cm. All patients tolerated the four fractions with no adverse events. The current dose level is 6 Gy times 4 fractions to a total dose of 24 Gy. Histologically, the first 2 patients had viable tumor. The remaining 4 patients had no residual tumor in the specimen. The mean follow-up time was 1.9 years (range, 0.7-2.69). No toxicities and no change in renal function were noted. To date we have completed SRA in 6 patients. Mean age was 56.5 years. Female n = 3; Male n = 3. Mean tumor size: 1.67 cm. All patients tolerated the four fractions with no adverse events. The current dose level is 6 Gy times 4 fractions to a total dose of 24 Gy. Histologically, the first 2 patients had viable tumor. The remaining 4 patients had no residual tumor in the specimen. The mean follow-up time was 1.9 years (range, 0.7-2.69). No toxicities and no change in renal function were noted. ConclusionsWe have established that our targeting is precise utilizing the Novalis gating technology. We are extremely encouraged and cautiously optimistic with our initial results. We believe that pathologic confirmation of ablative technologies is essential for appropriate evaluation of efficacy. We have established that our targeting is precise utilizing the Novalis gating technology. We are extremely encouraged and cautiously optimistic with our initial results. We believe that pathologic confirmation of ablative technologies is essential for appropriate evaluation of efficacy." @default.
• W2088610618 created "2016-06-24" @default.
• W2088610618 creator A5001335930 @default.
• W2088610618 creator A5017599304 @default.
• W2088610618 creator A5045023682 @default.
• W2088610618 creator A5049621046 @default.
• W2088610618 creator A5059180561 @default.
• W2088610618 date "2008-09-01" @default.
• W2088610618 modified "2023-10-16" @default.
• W2088610618 title "Histologic Confirmation of SBRT of Moving Targets using Respiratory Gated Radiation Delivery" @default.
• W2088610618 doi "https://doi.org/10.1016/j.ijrobp.2008.06.1085" @default.
• W2088610618 hasPublicationYear "2008" @default.
• W2088610618 type Work @default.
• W2088610618 sameAs 2088610618 @default.
• W2088610618 citedByCount "0" @default.
• W2088610618 crossrefType "journal-article" @default.
• W2088610618 hasAuthorship W2088610618A5001335930 @default.
• W2088610618 hasAuthorship W2088610618A5017599304 @default.
• W2088610618 hasAuthorship W2088610618A5045023682 @default.
• W2088610618 hasAuthorship W2088610618A5049621046 @default.
• W2088610618 hasAuthorship W2088610618A5059180561 @default.
• W2088610618 hasBestOaLocation W20886106181 @default.
• W2088610618 hasConcept C126322002 @default.
• W2088610618 hasConcept C126838900 @default.
• W2088610618 hasConcept C19527891 @default.
• W2088610618 hasConcept C2989005 @default.
• W2088610618 hasConcept C534529494 @default.
• W2088610618 hasConcept C71924100 @default.
• W2088610618 hasConceptScore W2088610618C126322002 @default.
• W2088610618 hasConceptScore W2088610618C126838900 @default.
• W2088610618 hasConceptScore W2088610618C19527891 @default.
• W2088610618 hasConceptScore W2088610618C2989005 @default.
• W2088610618 hasConceptScore W2088610618C534529494 @default.
• W2088610618 hasConceptScore W2088610618C71924100 @default.
• W2088610618 hasIssue "1" @default.
• W2088610618 hasLocation W20886106181 @default.
• W2088610618 hasOpenAccess W2088610618 @default.
• W2088610618 hasPrimaryLocation W20886106181 @default.
• W2088610618 hasRelatedWork W141524600 @default.
• W2088610618 hasRelatedWork W1754602832 @default.
• W2088610618 hasRelatedWork W1841185769 @default.
• W2088610618 hasRelatedWork W1986465740 @default.
• W2088610618 hasRelatedWork W2049214470 @default.
• W2088610618 hasRelatedWork W2072926321 @default.
• W2088610618 hasRelatedWork W2155887765 @default.
• W2088610618 hasRelatedWork W2331072469 @default.
• W2088610618 hasRelatedWork W2902148150 @default.
• W2088610618 hasRelatedWork W4230870081 @default.
• W2088610618 hasVolume "72" @default.
• W2088610618 isParatext "false" @default.
• W2088610618 isRetracted "false" @default.
• W2088610618 magId "2088610618" @default.
• W2088610618 workType "article" @default.